

UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY

MEDICINE TO GO PHARMACIES, INC., on : Civil Action No. 2:16-cv-07717 (CCC)(MF)
behalf of plaintiff and the class members :
defined herein, :

Plaintiff,

SCHEDULING ORDER #3

v.

MACOVEN PHARMACEUTICALS, LLC,
PERNIX THERAPEUTICS HOLDINGS,
INC., and JOHN DOES 1-10,

Defendants.

THIS MATTER having come before the Court for a Settlement Conference on October 26, 2017, and the Court having requested an amended Scheduling Order, and for good cause shown:

IT IS on this 27 day of November, 2017 ORDERED as follows:


1 Fact discovery is to remain open through [January 24, 2018/February 28, 2018];

3 All affirmative expert reports shall be delivered by [February 28, 2018/March 31, 2018], with depositions of those experts to be taken and completed within thirty (30) days of receipt of the report.

4 All responding expert reports shall be delivered by [March 31, 2018/April 30, 2018], with depositions of those experts to be taken and completed within thirty (30) days of receipt of the report.

5 Any motions for class certification shall be filed by [April 30, 2018/May 31, 2018].

All other deadlines and provisions in the Court's prior Scheduling Orders (DE 15 and DE 34) not addressed above remain unchanged.



Hon. Mark Falk, U.S.M.J.